| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/06/2004 | WO2004037788A1 Bicyclic benzamide compounds as histamine h3 receptor ligand useful in the treatment of neurological diseases |
| 05/06/2004 | WO2004037783A2 Treatment of cognitive impairment using a selective dopamine d1 receptor agonist |
| 05/06/2004 | WO2004037781A1 Vitamin d analogues, compositions comprising said analogues and their use |
| 05/06/2004 | WO2004037779A1 Substituted tetralins and indanes and their use |
| 05/06/2004 | WO2004037773A1 Phenethanolamine derivative for the treatment of respiratory diseases |
| 05/06/2004 | WO2004037769A2 Cycloalkylamides and their therapeutic use as antiepileptic and anticonvulsant |
| 05/06/2004 | WO2004037750A2 Short-acting sedative hypnotic agents for anesthesia and sedation |
| 05/06/2004 | WO2004037373A2 CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF β-GLUCOSIDASE |
| 05/06/2004 | WO2004037314A2 Patch and kit containing delayed-type hypersensitivity inducer |
| 05/06/2004 | WO2004037311A2 Device and methods for sequential, regional delivery of multiple cytotoxic agents |
| 05/06/2004 | WO2004037292A1 Colon cleansing compositions |
| 05/06/2004 | WO2004037291A1 Pharmaceutical product for endonasal administration for treating central nervous system diseases and disorders |
| 05/06/2004 | WO2004037290A1 Sustained release composition for oral administration of drugs |
| 05/06/2004 | WO2004037289A2 Novel injectable depot formulations |
| 05/06/2004 | WO2004037274A1 Amine polymers for promoting bone formation |
| 05/06/2004 | WO2004037273A1 Therapeutic and/or preventive agent for dyschezia |
| 05/06/2004 | WO2004037272A1 Dengue virus infection inhibitor |
| 05/06/2004 | WO2004037271A1 Cyclooxygenase regulation with ps liposomes |
| 05/06/2004 | WO2004037270A1 Cyclooxygenase regulation with pg liposomes |
| 05/06/2004 | WO2004037269A1 Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy |
| 05/06/2004 | WO2004037268A1 Prostaglandin compounds for the treatment of obesity |
| 05/06/2004 | WO2004037267A1 Method and composition containing latanoprost for treating ocular hypertension and glaucoma |
| 05/06/2004 | WO2004037266A1 Compounds for the treatment of cough |
| 05/06/2004 | WO2004037265A1 Prolonged release pharmaceutical composition |
| 05/06/2004 | WO2004037264A1 Water-soluble meloxicam granulates |
| 05/06/2004 | WO2004037263A1 Pharmaceutical compositions of ganciclovir |
| 05/06/2004 | WO2004037262A2 Immediate release topical pharmaceutical formulation for enhancement of female sexual desire and responsiveness |
| 05/06/2004 | WO2004037261A1 Use of n-‘5-‘4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension |
| 05/06/2004 | WO2004037260A1 Dosage form that is safeguarded from abuse |
| 05/06/2004 | WO2004037259A1 Dosage form that is safeguarded from abuse |
| 05/06/2004 | WO2004037258A1 A combination comprising combretastatin and anticancer agents |
| 05/06/2004 | WO2004037256A1 Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist |
| 05/06/2004 | WO2004037255A1 Use of tenatoprazole for the treatment of gastroesophageal reflux |
| 05/06/2004 | WO2004037254A1 Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent |
| 05/06/2004 | WO2004037252A1 A new crystalline form of the sodium salt of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid |
| 05/06/2004 | WO2004037251A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2 |
| 05/06/2004 | WO2004037250A1 4-alkenylthiazoles comprising epoxide functionality, and methods of use thereof |
| 05/06/2004 | WO2004037249A1 Agent for alleviation of functional disorder after cardiopulmonary resuscitation |
| 05/06/2004 | WO2004037248A2 Modulation of peroxisome proliferator activated receptors activity |
| 05/06/2004 | WO2004037247A1 Oxindoles with anti-hiv activity |
| 05/06/2004 | WO2004037246A1 Nerve fiber regeneration accelerator |
| 05/06/2004 | WO2004037245A1 Combination of a growth hormone receptor antagonist such as pegvisomant and a cox-2 inhibitor such as celecoxib for the treatment of headache in patients with acromegaly |
| 05/06/2004 | WO2004037244A1 Apparatus for the treatment of maxillary and frontal sinusitis and neuritis and neuralgia of the trigeminal nerve |
| 05/06/2004 | WO2004037243A2 Methods of treatment during vascular procedures |
| 05/06/2004 | WO2004037242A1 Painless injectable compositions containing salt of 2-arylpropionic acids |
| 05/06/2004 | WO2004037241A1 Fused cycloalkyl amides and acids and their therapeutic applications for the treatment of i.a. epilepsy |
| 05/06/2004 | WO2004037239A1 Antifungal medicaments based on arylamidine derivatives |
| 05/06/2004 | WO2004037238A1 New uses of deramciclane |
| 05/06/2004 | WO2004037237A1 Pharmaceutical compositions comprising flavonoids and menthol |
| 05/06/2004 | WO2004037236A1 OSTEOGENESIS PROMOTER CONTAINING β-CRYPTOXANTHIN AS THE ACTIVE INGREDIENT |
| 05/06/2004 | WO2004037235A2 Method and composition for preventing and treating solid tumors |
| 05/06/2004 | WO2004037234A2 Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| 05/06/2004 | WO2004037233A2 Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases |
| 05/06/2004 | WO2004037230A1 Dosage form that is safeguarded from abuse |
| 05/06/2004 | WO2004037229A1 Extended, controlled release pharmaceutical compositions comprising charged polymers |
| 05/06/2004 | WO2004037228A1 Sustained release compositions containing alfuzosin |
| 05/06/2004 | WO2004037227A1 Salmeterol superfine formulation |
| 05/06/2004 | WO2004037226A2 Pharmaceutical compositions containing venlafaxine |
| 05/06/2004 | WO2004037224A1 Depot formulations of arylheterocyclic active agents in the form of a suspension |
| 05/06/2004 | WO2004037212A2 Compositions comprising zopiclone derivatives and methods of making and using the same |
| 05/06/2004 | WO2004037211A2 Taxane metabolites |
| 05/06/2004 | WO2004037207A2 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| 05/06/2004 | WO2004037203A2 Sustained release l-arginine formulations and methods of manufacture and use |
| 05/06/2004 | WO2004037201A2 Topical skin care composition |
| 05/06/2004 | WO2004037200A2 Reticulocyte depletion signatures |
| 05/06/2004 | WO2004037199A2 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| 05/06/2004 | WO2004037197A2 Antifungal formulations |
| 05/06/2004 | WO2004037193A2 Chromones and chromone derivatives and uses thereof |
| 05/06/2004 | WO2004037192A2 Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases |
| 05/06/2004 | WO2004037190A2 Modified release compositions of milnacipran |
| 05/06/2004 | WO2004037187A2 Metal-containing materials, compositions and methods |
| 05/06/2004 | WO2004037186A2 Prophylactic treatment methods |
| 05/06/2004 | WO2004037184A2 Methods for the treatment of skin disorders |
| 05/06/2004 | WO2004037183A2 Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases |
| 05/06/2004 | WO2004037181A2 Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods |
| 05/06/2004 | WO2004037180A2 Compositions that treat or inhibit pathological conditions associated with inflammatory response |
| 05/06/2004 | WO2004037179A2 Substituted peptides useful in the treatment of alzheimer’s disease |
| 05/06/2004 | WO2004037175A2 Compositions and methods for treating human papillomavirus-mediated disease |
| 05/06/2004 | WO2004037173A2 Method for treating erectile dysfunction and increasing libido in men |
| 05/06/2004 | WO2004037172A2 Selenium bromide-oil-epichlorohydrin reaction products |
| 05/06/2004 | WO2004037171A2 Mitotic kinesin inhibitors |
| 05/06/2004 | WO2004037169A2 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 05/06/2004 | WO2004037165A2 Nitric oxide and its biomedical significance |
| 05/06/2004 | WO2004037164A2 Crosslinked compounds and methods of making and using thereof |
| 05/06/2004 | WO2004037163A2 STERICALLY-AWKWARD β-LACTAMASE INHIBITORS |
| 05/06/2004 | WO2004037162A2 Compositions and methods for the treatment of hepatitis c virus infection |
| 05/06/2004 | WO2004037159A2 Compounds, compositions and methods for modulating fat metabolism |
| 05/06/2004 | WO2004037120A2 Implantable medical devices using zinc |
| 05/06/2004 | WO2004037015A1 Antioxidative Compositions |
| 05/06/2004 | WO2004030678A3 Polymer compositions containing bioactive agents and methods for their use |
| 05/06/2004 | WO2004028441A3 Heterocyclic compound for stimulating or inducing hair or eyelash growth and/or for slowing down hair loss, composition containing same, and uses thereof |
| 05/06/2004 | WO2004024133B1 Novel pharmaceutical formulations of modafinil |
| 05/06/2004 | WO2004022041A3 Treatment of non-allergic rhinitis by means of selective phosphodiesterase-4 inhibitors |
| 05/06/2004 | WO2004021992A9 Delivery of therapeutics to the brain and spinal cord |
| 05/06/2004 | WO2004021975A3 An improved process for the synthesis of pharmacologically active (z/e)-guggulsterones |
| 05/06/2004 | WO2004021974A3 Non-psychotropic cannabinoids for prevention of cognitive impairment |
| 05/06/2004 | WO2004018457A8 Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors |
| 05/06/2004 | WO2004018451A8 Pyridazinone-derivatives as pde4 inhibitors |
| 05/06/2004 | WO2004018044A3 N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent |
| 05/06/2004 | WO2004017918A3 Method of preparing dry powder inhalation compositions |